Clearside Biomedical (FRA:CLM) Buyback Yield % : -28.33 (As of Apr. 11, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Clearside Biomedical Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Clearside Biomedical's current buyback yield was -28.33%.

Clearside Biomedical Buyback Yield % Historical Data

The historical data trend for Clearside Biomedical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Buyback Yield % Chart

Clearside Biomedical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-11.21

-14.38

-0.88

-2.34

-21.98

Clearside Biomedical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-2.27	-13.71	-15.77	-15.86	-22.53

Competitive Comparison of Clearside Biomedical's Buyback Yield %

For the Biotechnology subindustry, Clearside Biomedical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearside Biomedical's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Clearside Biomedical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Clearside Biomedical's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	15.651)	/	71.21754
	=	-21.98%

Clearside Biomedical's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	15.651)		/	71.21754
	=	-21.98%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Clearside Biomedical Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearside Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (FRA:CLM) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

CLSD:USA CLM:Germany

Address

900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005

Website

https://www.clearsidebio.com

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.